VivoSim Labs, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIVS research report →
Price Chart
About the company
VivoSim Labs, Inc. , a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.
- CEO
- Keith Murphy
- IPO
- 2012
- Employees
- 15
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on VIVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.33M
- P/E
- -0.03
- PEG
- 0.00
- P/S
- 14.76
- P/B
- 0.27
- EV/EBITDA
- 0.60
- Div Yield
- 0.00%
- Gross Margin
- -162.22%
- Op Margin
- -8897.78%
- Net Margin
- -7605.93%
- ROE
- -498.57%
- ROIC
- -154.91%
Latest fiscal year · YoY change
- Revenue
- $131.00K-9.0%
- Gross Profit
- $131.00K-5.8%
- Op Income
- $-11,224,000
- Net Income
- $-13,843,000-456.4%
- EPS
- $-5.35-214.7%
- OCF Growth
- -14.4%
- FCF Growth
- -14.3%
- 52W High
- $3.40
- 52W Low
- $0.12
- 50D MA
- $0.18
- 200D MA
- $0.94
- Beta
- 1.56
- RSI (14)
- 67
- Avg Volume
- 13.67M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Organovo said its liver tissue program needs more preclinical and manufacturing work, pushing key clinical milestones into 2021 while the company trimmed expenses and preserved cash runway.· May 22, 2019
- IND-enabling milestones for the liver therapeutic tissue program were delayed by a few quarters, with the pre-IND meeting now expected in calendar 2020 and IND submission/first-in-human trials planned for calendar 2021.
- Rodent data showed shorter durability than earlier pilot studies: human protein output dropped to nominal levels after about 1 month in current studies versus up to 3 months previously, though toxic globule reduction in the Alpha-1-antitrypsin model persisted to 90 days.
- Management is focusing nearly all resources on improving CMC, manufacturing, and preclinical data quality before meeting the FDA.
- The company still sees no adverse effects to date in well over 500 animals treated with its liver patches.
- Cash remained solid at $36.5 million at quarter-end, supported by $6.3 million of ATM proceeds, and management expects liquidity through the forecasted IND submission in 2021.
Organovo reported fiscal fourth quarter revenue of $0.7 million, down 38% year over year, with R&D expense of $4.4 million, up 11% year over year, and SG&A of $3.3 million, down 25% year over year. Net loss was $7 million, an improvement of $0.5 million from the year-ago quarter, and net cash utilization was $5.1 million versus $5.7 million in the prior-year period. Cash and cash equivalents were $36.5 million at the end of March, including $6.3 million of net proceeds from ATM sales of 6.1 million shares. For fiscal 2020, management forecast net cash utilization of $20 million to $22 million and said it expects sufficient funds, along with ATM usage, to meet operating and capital needs through the forecasted IND submission in calendar 2021.
Taylor Crouch framed the quarter around a reset of the development plan rather than a breakthrough quarter. He said the company is extending preclinical testing and refining manufacturing because current animal data show less durable function than earlier pilot work, but emphasized that this is part of building a stronger, more data-rich package for the FDA. His tone was cautious but determined, stressing that the company is devoting substantially all resources to the liver therapeutic tissue program and still believes the platform could address high-unmet-need indications such as end-stage liver disease, Alpha-1-antitrypsin deficiency, and bridge-to-transplant use.
Craig Kussman focused on a cleaner cost structure and a manageable cash profile. He said the quarter’s net loss improved to $7 million and net cash utilization fell to $5.1 million, helped by a 10% reduction in total expenses, including lower employee costs; R&D rose to $4.4 million from higher lab supplies, while SG&A fell to $3.3 million. He also highlighted $36.5 million in cash and cash equivalents at March quarter-end, $6.3 million of ATM proceeds, expected 2020 cash burn of $20 million to $22 million, and confidence that the company can fund itself through the planned 2021 IND submission.
Analysts pressed management on why the liver patch’s human protein output fell to nominal levels after about 1 month in current rodent studies, and whether the issue reflected inconsistent viability or simply better statistical power. Crouch answered that animal models are imperfect translational tools, that the company is working to improve measurement and standardization, and that manufacturing changes should improve starting viability and durability. Questions also probed the rationale for beginning first-in-human work in end-stage liver disease; Crouch said that setting creates a safety-focused basket-like entry point that can later branch into specific inborn errors of metabolism and possibly bridge-to-transplant use. Craig Kussman also confirmed the 10-K timing in the first week of June was normal and tied to the company’s usual audit schedule.
The company still believes its liver patch showed meaningful biology, including toxic globule reduction out to 90 days and no adverse liver enzyme or histology findings in well over 500 treated animals. Management sees the delay as a way to strengthen the CMC package, improve reproducibility, and enter the FDA process with better data, while cash of $36.5 million and expected ATM access provide runway through the planned 2021 IND submission.
The main risk is that the latest animal data showed shorter durability and lower protein output than prior pilot studies, creating uncertainty about whether the product can maintain function long enough for human use. The timeline has shifted by a few quarters, revenue is expected to keep fluctuating and likely trend down as the company de-emphasizes revenue-generating collaborations, and the business remains highly dependent on successful preclinical and manufacturing fixes before it can reach the clinic.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.4%
- Shares Outstanding
- 16.59M
- Float Shares
- 13.83M
of shares held by institutions
24 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 390.43K | ▲ 390.43K |
| Jane Street Group, LLC | 46.99K | ▲ 46.99K |
| Vanguard Group Inc | 22.37K | 0 |
| Geode Capital Management, LLC | 20.17K | ▼ 5.80K |
| Vanguard Capital Management LLC | 15.37K | 0 |
| Blackrock, Inc. | 10.34K | ▼ 1.48K |
| Ubs Group AG | 9.12K | ▲ 9.10K |
| Vanguard Fiduciary Trust Co | 7.00K | 0 |
| Tower Research Capital LLC (Trc) | 6.02K | ▲ 772 |
| Allworth Financial LP | 500 | ▲ 500 |
| Larson Financial Group LLC | 166 | 0 |
| Wells Fargo & Company/Mn | 136 | ▲ 25 |
Held by 4 ETFs
Biggest fund positions in VIVS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 31, 26 | Lialin Tony Serge | buy | 10,000 |
| Jan 27, 26 | Cohen Douglas Jay | other | 15,000 |
| Jan 27, 26 | Murphy Keith | other | 15,000 |
| Jan 27, 26 | Milhous Alison Tjosvold | other | 15,000 |
| Jan 27, 26 | Gobel David | other | 15,000 |
| Jan 27, 26 | STERN ADAM K | other | 15,000 |
| Nov 25, 25 | Sethi Amar Akhtar | other | 53,500 |
| Nov 24, 25 | Sethi Amar Akhtar | other | 0 |
| Nov 17, 25 | Gobel David | sell | 3,266 |
| Aug 11, 25 | Lialin Tony Serge | other | 40,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VIVS coverage
Recent articles, reports, and earnings notes.
No research on VIVS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VIVS report →VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
globenewswire.com · Nov 19
VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting
globenewswire.com · Nov 16
VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting
globenewswire.com · Nov 10
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
globenewswire.com · Nov 3
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
globenewswire.com · Oct 21
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
globenewswire.com · Oct 7
VivoSim Labs (NASDAQ:VIVS) vs. iSpecimen (NASDAQ:ISPC) Head to Head Comparison
defenseworld.net · Sep 30
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
globenewswire.com · Sep 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.